The safety profile of potassium DCA mirrors that of sodium DCA, since the active moiety — the dichloroacetate anion — is the same. The risks and precautions are therefore identical.

Peripheral neuropathy is the primary concern with extended DCA use. It is dose-dependent and duration-dependent, manifesting as tingling, numbness, or pain in the extremities. It is generally reversible upon cessation. The 2-weeks-on, 1-week-off cycle protocol was developed specifically to reduce this risk.

MCA contamination is a separate and more acute risk. Monochloroacetate — the toxic mono-chlorinated analogue — can contaminate DCA through poor synthesis or degradation. It is invisible to standard purity testing and requires separate ion chromatography testing to detect. This risk applies equally to potassium DCA: a potassium DCA supplier who does not test for MCA is selling an incompletely characterised product.

B1 (thiamine) supplementation is referenced alongside extended DCA use in the research literature. Alpha lipoic acid is sometimes also mentioned.

Monitoring liver function is advisable for extended protocols. No cardiac, pulmonary, or renal toxicity has been reported at research-relevant doses for either salt form.

This article is for informational and educational purposes only. AuraDCA products are intended for research use only.